NewKerala.com

India Pharma Exports Soar 9.4%, Eyeing Global Market Dominance

India's pharmaceutical exports grew 9.4% year-on-year to reach $30.47 billion in FY 2024-25, positioning the country as the third-largest producer by volume globally. The domestic market, valued at $60 billion, is projected to expand to $130 billion by 2030. Industry leaders engaged in high-level meetings with government officials to discuss strategic priorities and policy alignment for sustained export-led growth. Key initiatives like Chintan Shivir and iPHEX 2026 are highlighted as critical platforms for fostering innovation and global competitiveness, especially for MSMEs.

Key Points: India Pharma Exports Hit $30.47B, Growth at 9.4% in FY25

  • Exports hit $30.47B with 9.4% growth
  • Domestic market to reach $130B by 2030
  • Industry seeks policy alignment for global expansion
  • Focus on innovation and MSME support
2 min read

India's pharma sector bullish on pushing up exports

India's pharmaceutical exports reach $30.47B with 9.4% growth. Sector eyes $130B domestic market by 2030 and global expansion.

"India's pharmaceutical sector stands at a pivotal inflection point. - Namit Joshi"

New Delhi, Jan 5

India's pharmaceutical exports reached $30.47 billion in FY 2024-25, registering a 9.4 per cent year-on-year growth, and are on track to surpass last year's performance in the current financial year, the Pharmaceuticals Export Promotion Council of India informed Commerce Secretary Rajesh Agrawal on Monday.

PHARMEXCIL also highlighted India's position as the third-largest pharmaceutical producer globally by volume and a trusted supplier of affordable, quality-assured medicines to over 150 countries, which reflects the potential for long-term export-led growth.

The leadership of PHARMEXCIL held a series of high-level meetings with senior officials of the Centre to deliberate on strategic priorities, policy alignment, and growth opportunities for strengthening India's pharmaceutical exports, according to a statement issued by the trade body.

In a separate meeting with Secretary, Department of Pharmaceuticals, Manoj Joshi, the PHARMEXCIL highlighted the performance and growth trajectory of the pharmaceutical sector.

India's domestic pharmaceutical market, currently valued at approximately $60 billion, is projected to grow to $130 billion by 2030, the trade body said.

Discussions with Joint Secretary, Department of Pharmaceuticals, Satya Prakash L., focused on strengthening industry-academia collaboration across key segments, including clinical trials, biopharmaceuticals, vaccines, and APIs, with an emphasis on innovation, skill development, and capacity building.

The delegation also met Director General, Foreign Trade, Lav Aggarwal, to brief him on PHARMEXCIL's key initiatives and to seek continued support for programmes such as Chintan Shivir and iPHEX 2026.

Commenting on the engagements, PHARMEXCIL Chairman, Namit Joshi, said: "India's pharmaceutical sector stands at a pivotal inflection point. With strong export momentum, a rapidly expanding domestic market, and consistent government support, we are well-positioned to scale our global footprint while reinforcing India's reputation as a trusted pharmacy of the world."

iPHEX 2026 & PHARMEXCIL MSME Committee Chairman, Nipun Jain, added: "Platforms like Chintan Shivir and iPHEX are critical enablers for MSMEs and exporters. They not only facilitate market access but also foster dialogue around quality, innovation, and global competitiveness."

- IANS

Share this article:

Reader Comments

R
Rohit P
Great numbers, but I hope this growth trickles down. We need to ensure the MSMEs in this sector get the real benefits and support. Platforms like Chintan Shivir are a good step. Focus on innovation and quality is key to staying ahead.
A
Arjun K
$130 billion domestic market by 2030? That's huge potential. But alongside exports, we must also focus on making medicines even more affordable for our own population. The 'Pharmacy of the World' must also care for its home first.
S
Sarah B
As someone who has worked with global health agencies, India's role is indispensable. The consistency in quality and scale is remarkable. The emphasis on industry-academia collaboration for vaccines and biopharma is the right way forward.
V
Vikram M
Respectfully, while the export numbers are good, we are still heavily dependent on China for APIs (Active Pharmaceutical Ingredients). True strength will come when we are self-reliant in the entire value chain. Hope that's a top priority in these meetings.
N
Nisha Z
This sector creates so many jobs for science graduates! The projected growth means more opportunities in R&D, manufacturing, and quality control. A bright spot for our economy. Jai Hind!

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50